Hyperion DeFi (NASDAQ:HYPD – Get Free Report) announced its quarterly earnings data on Thursday. The company reported $0.26 EPS for the quarter, FiscalAI reports. The business had revenue of $0.24 million during the quarter.
Hyperion DeFi Stock Down 8.3%
NASDAQ HYPD traded down $0.30 during midday trading on Friday, hitting $3.32. 341,353 shares of the company traded hands, compared to its average volume of 403,379. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.68 and a quick ratio of 2.68. The company has a market cap of $40.57 million, a PE ratio of -0.28 and a beta of 2.57. The company’s 50-day simple moving average is $3.62 and its 200-day simple moving average is $3.90. Hyperion DeFi has a 52 week low of $1.08 and a 52 week high of $17.18.
Institutional Investors Weigh In On Hyperion DeFi
A number of institutional investors have recently added to or reduced their stakes in HYPD. Renaissance Technologies LLC purchased a new stake in shares of Hyperion DeFi during the fourth quarter valued at about $663,000. Jane Street Group LLC purchased a new position in shares of Hyperion DeFi in the 4th quarter worth approximately $493,000. Focus Partners Advisor Solutions LLC bought a new position in shares of Hyperion DeFi during the 4th quarter worth approximately $221,000. Geode Capital Management LLC bought a new position in shares of Hyperion DeFi during the 4th quarter worth approximately $214,000. Finally, Investment House LLC purchased a new stake in Hyperion DeFi during the fourth quarter valued at approximately $166,000. Institutional investors own 25.84% of the company’s stock.
Analysts Set New Price Targets
Check Out Our Latest Analysis on Hyperion DeFi
About Hyperion DeFi
Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.
See Also
- Five stocks we like better than Hyperion DeFi
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Hyperion DeFi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperion DeFi and related companies with MarketBeat.com's FREE daily email newsletter.
